The successful translation of these potential radiopharmaceutical precursors will not only enable a more comprehensive range of CXCR4-based radiopharmaceuticals, which will help the drugs be effective against a wider range of cancer types, but will also hopefully address the shortcomings of existing CXCR4-based radiopharmaceuticals with high hepatotoxicity. Here, CXCR4 is linked to cancer.